Loading...
Uploaded by FinancialNewsOnline on Feb 11, 2011
Shares of BioCryst (BCRX) are higher in morning trade as the company is reportedly upgraded to Buy from Underperform at BofA/Merrill. The firm made the call citing the gout drug BCX4208 potential for the upgrade. The firm has a $7 price target on company shares. That is up from $5.
News & Politics
Standard YouTube License
Load more suggestions
Link to this comment:
All Comments (0)